Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
Status:
Suspended
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of adjuvant adoptive cell therapy (ACT)
via infusion of LN-144 (autologous TIL) followed by interleukin-2 (IL-2) after a
nonmyeloablative lymphodepletion (NMA-LD) preparative regimen, followed by Pembrolizumab.